Background Older adults with dementia are vulnerable to the central deteriorating effects of drugs with anticholinergic properties (DAPs). These effects include falls and confusion and may exacerbate dementia-related symptoms. Many individuals with dementia also receive acetylcholinesterase inhibitors (AChEIs), indicated for mild to moderate Alzheimer's disease. AChEIs have opposing effects to DAPs and, consequently, concomitant use of DAPs and AChEIs may further impair cognition among patients with dementia. Objectives Our objectives were to (1) evaluate the anticholinergic burden among nursing home (NH) residents with dementia; (2) characterize trends in use of DAPs and concomitant use of DAPs and AChEIs among NH residents with dementia; and (3) 
Introduction
Fifty percent of nursing home (NH) residents have Alzheimer's disease or related dementias (ADRD) and 64 % of all Medicare beneficiaries living in an NH have ADRD [1, 2] . Compared with Medicare beneficiaries without ADRD, those with ADRD are more likely to have other chronic conditions such as urinary incontinence, angina, glaucoma, sleep disturbances, heart failure, and psychiatric disorders that are often treated with anticholinergic drugs or drugs with anticholinergic properties (DAPs) [2] [3] [4] [5] .
Use of DAPs in older adults with ADRD is a concern because the combined effects of polypharmacy, co-morbidities, and age-related changes in pharmacokinetic and pharmacodynamic parameters make patients more vulnerable to the central deteriorating effects of DAPs [4] [5] [6] [7] . These effects include falls, confusion, cognitive impairment, sedation, delirium, and increased risk of frailty [6, 8, 9] . Because age and ADRD are both associated with central cholinergic deficiency, DAP use may exacerbate dementiarelated symptoms [6] .
Individuals with ADRD may also receive acetylcholinesterase inhibitors (AChEIs), one of the two major drug classes approved by the US FDA for the treatment of ADRD [10] . AChEIs, including donepezil, galantamine, rivastigmine, and tacrine, are the only drugs with indications for mild to moderate Alzheimer's disease and have become the standard of care for managing dementia [10, 11] . AChEIs improve cholinergic neurotransmission, primarily through inhibition of the catabolic enzyme acetylcholinesterase, which degrades acetylcholine in the synaptic cleft [10] . Due to their opposing effects, concomitant use of DAPs and AChEIs may further impair cognition among patients with dementia, yet several studies have reported that concomitant use of DAPs and AChEIs is common among older residents of NHs [3, [12] [13] [14] [15] [16] [17] .
Previous studies that examined anticholinergic use among NH residents with ADRD evaluated prevalence and predictors of DAP use during a single year or concomitant use of DAPs and AChEIs, but none have evaluated time trends in DAP use or predictors of concomitant DAP and AChEI use [6, [12] [13] [14] [15] [16] [17] . The goals of this study were to (1) evaluate the anticholinergic burden among NH residents with dementia; (2) characterize trends in the use of DAPs and concomitant use of DAPs and AChEIs among NH residents with dementia; and (3) identify factors associated with the use of DAPs and concomitant use of DAPs and AChEIs.
Methods

Study Design and Data Source
This retrospective study used data from a 5 % random sample of Medicare beneficiaries from 2006 to 2008. Medicare administrative data were obtained from the Centers for Medicare & Medicaid Services (CMS) Chronic Condition Data Warehouse (CCW). Medicare enrollment and claims data were linked to the Minimum Data Set 2.0 (MDS). The MDS is part of the US federally mandated process for clinical assessment of all residents in Medicareor Medicaid-certified NHs and provides comprehensive assessments of each resident's physical, psychological, and psychosocial functioning. These assessments are required for residents on admission to the nursing facility and then periodically thereafter, during discharges, quarterly audits, or transfers.
Cohort Selection
The CCW identifies 27 chronic conditions, including ADRD, and contains an annual flag for each condition. An annual flag for ADRD requires at least one inpatient, skilled nursing facility (SNF), home health agency, hospital outpatient, or carrier (physician) claim with a dementia diagnosis [ 
Drug Measures/Drug Use
The primary exposures for this study were DAP and AChEI use. In this study of NH residents with dementia, we were interested in the cognitive burden of DAPs. Therefore, we identified and classified DAPs based on the Indiana Drug Discovery Network Anticholinergic Cognitive Burden Scale (ACBS), which, unlike other anticholinergic drug scales, specifically targets the cognitive effects of DAPs [19] [20] [21] . The ACBS is derived from a list of 82 DAPs that have an acute negative impact on cognition. DAPs are scored from 1 to 3 [19, 20] . Medications with an ACBS score of 1 have serum anticholinergic activity, but their clinical impact on cognition has not been confirmed in research studies. Medications with established and clinically relevant cognitive anticholinergic effects have scores of 2 or 3 based on increasing anticholinergic activity [19, 20] . The sum of the ACBS for each DAP equals the monthly ACBS for each resident. In this study, AChEIs included donepezil, galantamine, and rivastigmine.
We searched for all DAPs and AChEIs in the Medicare Part D PDE file and calculated the proportion of days covered (number of daily doses/30-day month) for all DAPs and AChEIs in each month. DAP and AChEI use were dichotomous variables defined as a proportion of days covered greater than zero during the month. We also created variables indicating any definite DAP (ACBS score 2-3) use and concomitant definite DAP and AChEI use in each month. We used three methods to calculate average monthly anticholinergic burden: (1) ACBS; (2) count of DAP: the number of unique DAPs used each month; and (3) daily anticholinergic burden (DACB): average daily burden in each month, calculated by dividing the sum of each day's ACBS by the total number of days in the month.
Covariates
Demographic characteristics and co-morbidities were obtained from the CCW file. Baseline co-morbid conditions were based on CCW flags from the prior year. Behavioral, cognitive, and functional factors derived from MDS assessments included the Aggressive Behavior Scale (ABS), Cognitive Performance Scale (CPS), and activities of daily living (ADL) [22] [23] [24] . Baseline values were from the first MDS assessment during the NH stay, and were carried forward until the next MDS assessment. The ABS is a measure of aggressive behavior based on the occurrence of verbal abuse, physical abuse, socially disruptive behavior, and resistance of care. Scale scores range from 0 to 12, with higher scores indicative of greater frequency and diversity of aggressive behavior [22] . The CPS combines information on memory impairment, level of consciousness, and executive function, with scores ranging from 0 (intact) to 6 (very severe impairment) [23] . ADL refers to daily self-care activities an individual performs and has scores ranging from 0 to 28, with lower scores indicating greater independence in physical functioning [24] .
Statistical Analysis
We calculated the average monthly prevalence of DAP and AChEI use and tested for time trends over the 2-year study period using Cochran-Armitrage tests. We also calculated the average monthly anticholinergic burden over the study period and the average monthly prevalence of DAP use by drug class among NH residents for level 1, 2, and 3 DAPs. To identify factors associated with the use of ACBS level 2 or 3 DAPs, we used generalized estimating equations with a Poisson distribution to account for clustering within residents and generated risk ratios (RRs) and 95 % confidence intervals. Similarly, we identified factors associated with ACBS level 2 or 3 DAPs and concomitant use of AChEIs. Because resident characteristics may change over the study period, we used time-varying ADL, ACBS, and CPS scores based on the most recent prior MDS assessment in our regression models. Due to large sample size, statistical significance was defined a priori as p \ 0.001. All analyses were performed with SAS Ò version 9.2 (SAS Institute, Cary, NC, USA).
Results
We During the study period, 77 % of NH residents with ADRD used at least one DAP each month on average (Fig. 1) . Sixty-seven percent of NH residents with ADRD used ACBS level 1 DAPs, 3 % used level 2 DAPs, and 31 % used level 3 DAPs. Thirteen percent of NH residents with ADRD concomitantly used ACBS levels 2 or 3 DAPs and AChEIs within the same month. Among AChEI users, the average monthly prevalence of DAP use was 81 %, and 37 % used level 2 or 3 DAPs. There were small but significant negative trends over the 2-year study period in any DAP use (77. (Fig. 1) . Among DAP users, the average monthly ACBS was moderate at 3.1 (SD 2.1) and the average DACB each month was 2.6 (SD 1.8) ( Table 2 ). The average number of DAPs used per month was 2.1 (SD 1.2).
Among DAP level 1 users, the most commonly used drug classes were antipsychotics (16 %) and bladder antispasmodics (8 %). Among DAP level 2 users, the most commonly used drug classes were anticonvulsants (48 %), antipsychotics (22 %), and central anticholinergics (16 % 
Discussion
DAP use was common among NH residents with ADRD. One-third used DAPs with known anticholinergic effects (ACBS level 2 and 3), but concomitant use of ACBS level 2 or 3 DAPs and AChEIs was less common. We identified several patient factors associated with use of [6, 16] . A prior study reporting anticholinergic burden used the Anticholinergic Drug Scale rather than the ACBS to categorize anticholinergic activity, making comparisons with our study on the levels of DAPs used difficult [6, 25] .
Few studies have examined the prevalence of AChEI use among DAP users. A study conducted among individuals in residential care in Finland reported 27 % concomitant use of AChEIs or memantine among DAP users [12] . This is consistent with our reported estimate (25 %), although our study did not include memantine except to identify NH residents with ADRD. Two prior studies examined the prevalence of DAP use among users of AChEIs [15, 26] . In one study conducted in NHs in Indiana, 47 % of AChEI users with dementia used DAPs with known cognitive effects during the study period [15] . In the other, 37 % of community-dwelling AChEI users aged 50 years and older also used DAPs during the study period [26] . Our lower estimate of concomitant ACBS level 2 or 3 DAP use among NH residents with dementia who used AChEIs (37 %) is likely because of differences in measurement (any use vs. average monthly prevalence of use in our study).
In this cross-sectional study we identified factors associated with DAP and AChEI use, but determining predictors of use is more difficult. Nonetheless, antipsychotics constitute a large percentage of level 2 and 3 DAPs; hence, factors associated with level 2 or 3 DAP use may actually represent factors associated with antipsychotic use. In this context, the association between aggressive behavior and level 2 or 3 DAP use is likely due to the use of antipsychotics to control dementia-related behavioral symptoms [27, 28] . This study took place after the FDA issued the first black box warning on antipsychotics for the control of dementia-related behavioral symptoms in 2005 [29] . Therefore, beneficiaries with greater cognitive and physical impairment may have been less likely to receive antipsychotics, consistent with our results. Other observed associations between age, sex, cognition, and aggressive behavior and DAP or concomitant DAP/AChEI use are in accordance with previous research [6, 15, 26] .
Strengths of this study include use of nationally representative data to assess DAP use among Medicare beneficiaries with ADRD residing in a NH. In addition, this study is the first to report factors associated with concomitant use of DAPs and AChEIs among NH residents with ADRD. Finally, we used the ACBS, a well-validated scale used to measure anticholinergic activity that was developed based on a systematic review of literature and expert professional input [19] [20] [21] . Nonetheless, administrative claims data do not capture use of over-the-counter DAPs such as firstgeneration antihistamines, which may have resulted in an underestimation of the prevalence of DAP use. Furthermore, claims data are created for billing purposes and may be missing information, including co-morbidities such as ADRD. To address this limitation, we used three independent criteria to define our study population, increasing the specificity of our dementia definition. Finally, this study did not examine outcomes of DAP or 
